Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
Por um escritor misterioso
Descrição
PDF) Dupilumab provides favourable long-term safety and efficacy
Type 2 asthma in children managed by dupilumab, despite atopic
Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
FDA approves dupilumab for children aged 6 to 11 years with
DUPIXENT® (dupilumab) Dosage & Administration Information
New Drug a Good Treatment Option for Severe Asthma in Kids
Assessment of dupilumab in children with moderate‐to‐severe type 2
DUPIXENT® (dupilumab) for Moderate-to-Severe Atopic Dermatitis
Regeneron on LinkedIn: Late-Breaking Dupixent® (dupilumab) Data at
Dupilumab-improved lung function lasts in children with moderate
Sanofi, Regeneron Report Positive Phase 3 Results For Asthma Drug
Dupilumab leads to better-controlled asthma and quality of life in
FDA Approves Dupixent® as First Biologic for Treatment of Children
de
por adulto (o preço varia de acordo com o tamanho do grupo)
